-DOCSTART- -X- O
Targeting -X- _ O
papain -X- _ O
family -X- _ O
cysteine -X- _ O
proteases -X- _ O
is -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
novel -X- _ O
strategies -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
chemotherapy -X- _ O
for -X- _ O
a -X- _ O
number -X- _ O
of -X- _ O
diseases. -X- _ O
Novel -X- _ O
cysteine -X- _ O
protease -X- _ O
inhibitors -X- _ O
derived -X- _ O
from -X- _ O
1- -X- _ B-Intervention
pyridylimidazo -X- _ I-Intervention
[ -X- _ I-Intervention
1,5-a -X- _ I-Intervention
] -X- _ I-Intervention
pyridine -X- _ I-Intervention
representing -X- _ O
pharmacologically -X- _ O
important -X- _ O
class -X- _ O
of -X- _ O
compounds -X- _ O
are -X- _ O
being -X- _ O
reported -X- _ O
here -X- _ O
for -X- _ O
the -X- _ O
first -X- _ O
time. -X- _ O
The -X- _ O
derivatives -X- _ O
were -X- _ O
initially -X- _ O
designed -X- _ O
and -X- _ O
screened -X- _ O
in -X- _ O
silico -X- _ O
by -X- _ O
molecular -X- _ O
docking -X- _ O
studies -X- _ O
against -X- _ O
papain -X- _ O
to -X- _ O
explore -X- _ O
the -X- _ O
possible -X- _ O
mode -X- _ O
of -X- _ O
action. -X- _ O
The -X- _ B-Outcome
molecular -X- _ I-Outcome
interaction -X- _ I-Outcome
between -X- _ I-Outcome
the -X- _ I-Outcome
compounds -X- _ I-Outcome
and -X- _ I-Outcome
cysteine -X- _ I-Outcome
protease -X- _ I-Outcome
( -X- _ I-Outcome
papain -X- _ I-Outcome
) -X- _ I-Outcome
was -X- _ I-Outcome
found -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
very -X- _ I-Outcome
similar -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
interactions -X- _ I-Outcome
observed -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
respective -X- _ I-Outcome
epoxide -X- _ I-Outcome
inhibitor -X- _ I-Outcome
( -X- _ I-Outcome
E-64c -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
papain. -X- _ I-Outcome
Subsequently -X- _ O
, -X- _ O
compounds -X- _ O
were -X- _ O
synthesized -X- _ O
to -X- _ O
validate -X- _ O
their -X- _ O
efficacy -X- _ O
in -X- _ O
wet -X- _ O
lab -X- _ O
experiments. -X- _ O
When -X- _ O
characterized -X- _ O
kinetically -X- _ O
, -X- _ O
these -X- _ B-Outcome
compounds -X- _ I-Outcome
show -X- _ I-Outcome
their -X- _ I-Outcome
K -X- _ I-Outcome
( -X- _ I-Outcome
i -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
IC -X- _ I-Outcome
( -X- _ I-Outcome
50 -X- _ I-Outcome
) -X- _ I-Outcome
values -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
range -X- _ I-Outcome
of -X- _ I-Outcome
13.75 -X- _ I-Outcome
to -X- _ I-Outcome
99.30 -X- _ I-Outcome
μM -X- _ I-Outcome
and -X- _ I-Outcome
13.40 -X- _ I-Outcome
to -X- _ I-Outcome
96.50 -X- _ I-Outcome
μM -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
The -X- _ O
thermodynamics -X- _ O
studies -X- _ O
suggest -X- _ O
their -X- _ O
binding -X- _ O
with -X- _ O
papain -X- _ O
hydrophobically -X- _ O
and -X- _ O
entropically -X- _ O
driven. -X- _ O
These -X- _ O
inhibitors -X- _ O
also -X- _ O
inhibit -X- _ B-Outcome
the -X- _ I-Outcome
growth -X- _ I-Outcome
of -X- _ I-Outcome
clinically -X- _ I-Outcome
important -X- _ I-Outcome
different -X- _ I-Outcome
types -X- _ I-Outcome
of -X- _ I-Outcome
Gram -X- _ I-Outcome
positive -X- _ I-Outcome
and -X- _ I-Outcome
Gram -X- _ I-Outcome
negative -X- _ I-Outcome
bacteria -X- _ I-Outcome
having -X- _ I-Outcome
MIC -X- _ I-Outcome
( -X- _ I-Outcome
50 -X- _ I-Outcome
) -X- _ I-Outcome
values -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
range -X- _ I-Outcome
of -X- _ I-Outcome
0.6–1.4 -X- _ I-Outcome
μg -X- _ I-Outcome
/ -X- _ I-Outcome
ml. -X- _ I-Outcome
Based -X- _ O
on -X- _ O
Lipinski’s -X- _ O
rule -X- _ O
of -X- _ O
Five -X- _ O
, -X- _ O
we -X- _ O
also -X- _ O
propose -X- _ O
these -X- _ B-Outcome
compounds -X- _ I-Outcome
as -X- _ I-Outcome
potent -X- _ I-Outcome
antibacterial -X- _ I-Outcome
prodrugs. -X- _ I-Outcome
The -X- _ O
most -X- _ B-Outcome
active -X- _ I-Outcome
antibacterial -X- _ I-Outcome
compound -X- _ I-Outcome
was -X- _ I-Outcome
found -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
1- -X- _ I-Outcome
( -X- _ I-Outcome
2-pyridyl -X- _ I-Outcome
) -X- _ I-Outcome
-3- -X- _ I-Outcome
( -X- _ I-Outcome
2-hydroxyphenyl -X- _ I-Outcome
) -X- _ I-Outcome
imidazo -X- _ I-Outcome
[ -X- _ I-Outcome
1,5-a -X- _ I-Outcome
] -X- _ I-Outcome
pyridine -X- _ I-Outcome
( -X- _ I-Outcome
3a -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O

